Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio Inc. is focused on the development of innovative gene therapies for neurodegenerative diseases, specifically through their pipeline candidate PBFT02, which aims to address critical underlying pathologies. The company's management anticipates that an amended trial protocol may enable earlier intervention in the disease process, potentially enhancing the benefits derived from PBFT02, while also expediting trial timelines through the parallel enrollment of Cohort 3. Additionally, the opportunity for regulatory alignment on accelerated approval based solely on biomarker endpoints could significantly shorten those timelines, positioning Passage Bio favorably against competitors in the genetic medicine landscape.

Bears say

Passage Bio Inc faces significant challenges that contribute to a negative outlook on its stock, primarily related to clinical and manufacturing risks. The company is developing early-stage gene therapies, and any delays in clinical timelines or the emergence of safety concerns, such as immune reactions, could severely impact market sentiment and lead to downward revisions of financial forecasts. Additionally, the complexity of manufacturing AAV-based gene therapies may result in further delays in product development and commercialization, complicating the path to regulatory approval and hampering the company's growth prospects.

PASSAGE BIO (PASG) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PASSAGE BIO (PASG) has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.